How long does it take to see the effects of Cabozantinib?

Cabozantinib is a multi-target tyrosine kinase inhibitor mainly used to treat malignant tumors such as advanced renal cell carcinoma, hepatocellular carcinoma and medullary thyroid carcinoma. It inhibits tumor growth and metastasis by inhibiting various key signaling pathways such as VEGFR, MET, and AXL. Due to its broad target range, cabozantinib has shown good clinical effects in the treatment of a variety of solid tumors.

In actual use, the onset time of cabozantinib varies due to individual differences, disease progression rate, drug combination regimen and other factors. Under normal circumstances, some patients can observe signs of stabilization or shrinkage of tumor volume in imaging examinations within 4 to 8 weeks after taking the drug. Some patients also experience improvement in symptoms during this period, such as pain relief, increased physical strength, etc. However, for some patients with more complex conditions or slowly progressing lesions, it may take longer for significant effects to appear, ranging from 8 to 12 weeks or even longer.

In order to scientifically evaluate the efficacy of cabozantinib, patients need to undergo regular imaging examinations (such as CT or MRI) after taking the drug. It is usually recommended to conduct a review every 8 weeks or 12 weeks. In addition, doctors will comprehensively judge the effect of treatment based on changes in tumor markers, improvement in quality of life, and changes in symptoms. During this process, patients should not stop medication or change treatment plans at will because no obvious changes are seen in the short term. It is particularly important to patiently cooperate with treatment.

It should be noted that although cabozantinib has a relatively rapid onset of action, it may also be accompanied by adverse reactions such as hypertension, hand-foot syndrome, diarrhea, loss of appetite, etc. If serious side effects occur during treatment, the dose should be adjusted or the drug temporarily discontinued under the guidance of a doctor. Overall, most patients gradually see clinical benefit from cabozantinib within the first few months of treatment.

Reference materials:https://www.drugs.com/